Apellis Pharmaceuticals Inc

Biogen’s $5.6 B takeover of Apellis sends the stock soaring, unlocking rare‑disease drugs, a 140 % premium, and new growth upside for investors.

Apellis Pharmaceuticals Inc. has achieved a significant milestone with the FDA approval of EMPAVELI, a groundbreaking treatment for rare kidney disorders C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis.

Apellis Pharmaceuticals has secured FDA approval for its drug EMPAVELI, marking a significant milestone in the treatment of rare kidney disorders C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis.

Apellis Pharmaceuticals Inc. has secured FDA approval for EMPAVELI, a treatment for rare kidney disorders, marking a significant advancement in the field and a major milestone for the company.

Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering therapeutic compounds for autoimmune and inflammatory diseases, with a strong focus on innovation and a promising future in the biotechnology sector.

Apellis Pharmaceuticals’ stock has seen a 5.9% increase, bringing its price to $16.93, despite remaining below its 52-week high and facing market volatility.

Apellis Pharmaceuticals is facing significant financial challenges, including a lowered price target and weak performance of its product Syfovre, which has raised concerns about the company’s future prospects.

Apellis Pharmaceuticals reported Q1 2025 earnings, missing expectations with a GAAP EPS of -$0.74 and revenue of $166.8 million, but remains committed to advancing its pipeline and engaging with investors.

Apellis Pharmaceuticals Inc. reported disappointing Q1 earnings, but maintains a market capitalization of $2.52 billion, as the company prepares to engage with investors at upcoming conferences to discuss its strategic direction and pipeline progress.